I'm thinking it may have something to do with the fact that prior to the Ph3 trial commencement of treatment all participants including those dosed with the placebo were dosed with an antibiotic which is the current treatment for BV. I just can't think of a reason to take that approach as it may skew the results.
Wouldn't you think patients suffering from BV would go straight into the Vivagel treatment. if this is the case it's a new trial!!
DEP always first, page-15
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.001(1.02%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 9.6¢ | 10.0¢ | 9.6¢ | $5.703K | 58.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.41pm 11/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |